WBA - Walgreens Boots Alliance, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
51.77
+0.16 (+0.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close51.61
Open51.78
Bid51.65 x 3200
Ask51.77 x 800
Day's Range51.16 - 51.84
52 Week Range51.16 - 86.31
Volume4,296,034
Avg. Volume7,245,565
Market Cap47.333B
Beta (3Y Monthly)0.61
PE Ratio (TTM)9.72
EPS (TTM)5.33
Earnings DateJun 26, 2019 - Jul 1, 2019
Forward Dividend & Yield1.76 (3.29%)
Ex-Dividend Date2019-05-17
1y Target Est58.00
  • Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
    Zacks4 days ago

    Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know

    Walgreens Boots Alliance (WBA) closed the most recent trading day at $52.76, moving +0.96% from the previous trading session.

  • GuruFocus.com4 days ago

    52-Week Company Lows

    According to GuruFocus' list of 52-week lows, these Guru stocks have reached their 52-week lows. The price of 3M Co. (MMM) shares has declined to close to the 52-week low of $166.25, which is 24.5% off the 52-week high of $219.75. The company has a market cap of $95.83 billion.

  • Pharmacies & Drug Stores Industry Near-Term Prospects Bleak
    Zacks4 days ago

    Pharmacies & Drug Stores Industry Near-Term Prospects Bleak

    Pharmacies & Drug Stores Industry Near-Term Prospects Bleak

  • Better Buy: Walgreens Boots Alliance vs. CVS Health
    Motley Fool7 days ago

    Better Buy: Walgreens Boots Alliance vs. CVS Health

    Which retail pharma giant is the better choice for investors today?

  • Morningstar8 days ago

    Walgreens' Prescription for Growth

    Founded in 1901,  Walgreens Boots Alliance WBA is the leading pharmacy retailer, leveraging its scale to provide convenience. The company generates nearly $140 billion in revenue and dispenses over 1 billion prescriptions annually, representing one fourth of the drug market. Scale remains critical in an increasingly competitive market that has witnessed some rationalization of subscale peers.

  • Alphabet (GOOGL) Deepens Focus on Cardio Diseases with Verve
    Zacks9 days ago

    Alphabet (GOOGL) Deepens Focus on Cardio Diseases with Verve

    Alphabet (GOOGL) focuses on reducing risks of heart diseases by working on the development of one-time injectable treatment in collaboration with Verve Therapeutics.

  • Amazon's online drug push has one Bay Area start-up shifting its business to bolster retail pharmacies
    CNBC9 days ago

    Amazon's online drug push has one Bay Area start-up shifting its business to bolster retail pharmacies

    Nimble, a venture capital-backed start-up, wants to help thousands of independent pharmacies go digital.

  • CNBC9 days ago

    Amazon's online drug push has one start-up cutting staff and selling pharmacies to help businesses compete

    With Amazon's jump into the pharmacy business, Nimble is focusing on helping local pharmacies deliver to customers. There are about 20,000 independent pharmacies that have to stand up to Amazon while also fending off CVS and Walgreens. Nimble has raised over $60 million from venture investors including Sequoia and Khosla Ventures.

  • American City Business Journals9 days ago

    (PHOTOS) Analyst: LabCorp ripe for Walgreens acquisition

    Raymond James analyst John Ransom this week named two potential targets for Walgreens Boots Alliance (Nasdaq: WBA) – LabCorp and drug wholesaler AmerisourceBergen (NYSE: ABC).

  • Barrons.com10 days ago

    Bill & Melinda Gates Foundation Trust Sells Off Slumping Walgreens Stock

    The trust disclosed Wednesday night that it has sold all 3.5 million shares of the drugstore and pharmacy chain in the first quarter. Walgreens stock set a new low on Wednesday.

  • Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
    Zacks10 days ago

    Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know

    Walgreens Boots Alliance (WBA) closed the most recent trading day at $52.74, moving +0.3% from the previous trading session.

  • Amazon Stock Price Will Get Back to $2,000 and Keep Going
    InvestorPlace10 days ago

    Amazon Stock Price Will Get Back to $2,000 and Keep Going

    In this market, investors holding Amazon.com (NASDAQ:AMZN) likely are a bit worried. AMZN isn't cheap. Amazon.com's massive reach makes its sensitive to consumer demand. And the Amazon stock price already is dropping, falling over 7% in just the last six sessions.Source: Shutterstock And it wouldn't be a total surprise if AMZN stock fell even further. Shares declined by one-third in less than three months during the market declines of last year. Should trade war fears drive another broad market pullback, Amazon stock is unlikely to emerge unscathed.But from a long term standpoint, Amazon.com looks just fine, in fact better than fine. The Amazon stock price admittedly hasn't returned to last year's peaks. AMZN then traded at over $2,000 and briefly had a trillion-dollar market capitalization. But I expect it will get back to those levels and beyond, even if the wait might require some patience.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Trade War Stocks With a Lot of Risk The AMZN Stock BubbleFor most of the past decade, AMZN stock has been cited as the epitome of an overheated market. AMZN always has looked expensive, often trading at earnings multiples over 100x. It historically has generated little in the way of profit: operating margins were 2.3% as recently as 2017.The combination made AMZN seem like a symptom of a bubble. What would happen if the company stopped competing solely on price? For how long would investors keep paying nosebleed multiples for a company that went public last century? At some point, bears argued, Amazon stock inevitably would come back to Earth.Despite some stumbles over the years, the supposed bubble never popped and with good reason. Amazon earnings have stayed low because the company chose to kept them there. It has for years invested in back in business, trading profit dollars today for more profit dollars tomorrow (or, perhaps more accurately, five years from now).As I've argued for some time, simply looking at Amazon's P/E multiple is not the way to properly value its business. Amazon's high multiples haven't been the case, as bears have argued, of the market not paying attention. It's precisely the opposite, in fact. And that's why the Amazon stock price has managed to stay so elevated, for so long. Earnings Are RisingThe good news for Amazon stock is that the long term strategy remains in place, yet earnings are starting to soar regardless. Operating income tripled in 2018. Profits then more than doubled in Q1.Much of the growth is coming from Amazon Web Services, whose profits rose almost $3 billion in 2018 and another $800 million-plus in the first quarter of this year. International losses are starting to narrow as well: that business was nearly breakeven in Q1. North America sales continue to rise steadily, and profits in that segment, rose almost exactly 100% year-over-year in the first quarter.What makes AMZN stock attractive is that none of those trends are likely to change. North America margins still are in the 6% range, and have room to further expand over time, even if the rollout of one-day shipping should provide a near-term hit. Revenue growth is going to continue as more purchases move online. And advertising represents another billion-dollar opportunity at significantly higher margins.AWS continues to lead Microsoft (NASDAQ:MSFT) and Alphabet (NASDAQ:GOOG,NASDAQ:GOOGL) in cloud. International profits are on the way. Even assuming Amazon continues to invest in the business, and doesn't look to squeeze additional pricing dollars out of its customers, earnings are going to keep growing steadily. Amazon Stock to $2,000+So the argument that Amazon can't really make profits has been debunked, and slowly but surely the seemingly outlandish valuation is coming in. Consensus EPS estimates suggest a 67x multiple to 2019 EPS and a sub-50x multiple to 2020 EPS.Earnings next year are expected to 40%; even a deceleration means Amazon's multiples starting getting closer to that of other tech stocks in reasonably short order.But there's really no reason why the Amazon stock price should trade in line with other tech stocks. It is a company that dominates enormous industries and has room to enter even more.One big reason why Walgreens (NASDAQ:WBA) and CVS Health (NYSE:CVS) are trading at the lows is that Amazon acquired PillPack last year, and can challenge their dominance in prescriptions. Prime Video and Prime Music still have room for growth. The same is true for the acquisition of Whole Foods Market and other efforts to return to brick-and-mortar retail.EPS likely heads near $40 next year. There's no reason why it can't get to $80 over the next five years (that would represent just 15% annual growth, a notable deceleration from recent performance). Give AMZN even a 40x multiple and the stock rises to $3,200. Discounted back at 10%, that in turn values AMZN at almost exactly $2,000 right now.In other words, even if Amazon's growth slows, and its earnings multiple comes in, its stock still is undervalued. It might seem hard to believe given how expensive the stock has looked for so long. And while it's hardly cheap now, as long as Amazon keeps doing what it is doing, it will look cheap much sooner than investors might think.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post Amazon Stock Price Will Get Back to $2,000 and Keep Going appeared first on InvestorPlace.

  • Moody's11 days ago

    BioScrip, Inc. -- Moody's upgrades BioScrip, Inc.'s Corporate Family Rating to B3, outlook stable

    Moody's Investors Service ("Moody's") today upgraded the Corporate Family Rating (CFR) of BioScrip, Inc. ("BioScrip") to B3 from Caa1 and upgraded the Probability of Default to B3-PD from Caa1-PD. At the same time, Moody's upgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-4 and assigned a B2 (LGD 3) rating to the proposed $925 million First Lien Term Loan B. The outlook is stable. The upgrade reflects the improvement in BioScrip's credit profile due to the pending merger with HC Group Holdings III, Inc. (dba Option Care).

  • What Wall Street Recommends for Walgreens Stock
    Market Realist12 days ago

    What Wall Street Recommends for Walgreens Stock

    Walgreens Boots Alliance Stock: Is Recovery a Long Shot?(Continued from Prior Part)Earnings expected to decline Wall Street expects Walgreens Boots Alliance’s (WBA) earnings to continue to decline in coming quarters, reflecting higher

  • Walgreens Boots Alliance Stock: Is Recovery a Long Shot?
    Market Realist12 days ago

    Walgreens Boots Alliance Stock: Is Recovery a Long Shot?

    Walgreens Boots Alliance Stock: Is Recovery a Long Shot?Stock performance Walgreens Boots Alliance (WBA) stock is down about 17% since the company announced its weak fiscal 2019 second-quarter earnings on April 2. Moreover, management lowered the

  • CVS Health Corporation (CVS) and Walgreens Boots Alliance, Inc. (WBA): The Vilas Fund’s Latest Thoughts
    Insider Monkey12 days ago

    CVS Health Corporation (CVS) and Walgreens Boots Alliance, Inc. (WBA): The Vilas Fund’s Latest Thoughts

    The Vilas Fund recently published its Q1 2019 Investor Letter (download here), in which it shares its quarterly performance, reporting 34.3% gain in the period. The fund also posted short comments on several holdings, among which were CVS Health Corporation (NYSE:CVS) and Walgreens Boots Alliance, Inc. (NASDAQ:WBA). For these two companies, The Vilas Fund said […]

  • Business Wire12 days ago

    Walgreens Boots Alliance Announces Collaboration for Cancer Prevention, Research and Support

    Walgreens Boots Alliance, Inc. (WBA) announced today the launch of its Collaboration for Cancer Prevention, Research and Support, a transatlantic charitable partnership between the company and leading European, British and American cancer organizations to support people living with cancer at all moments of their journey. WBA gathered recently with leaders from the European Organisation for Research and Treatment of Cancer (EORTC), Macmillan Cancer Support and Susan G. Komen® as they officially launched the Collaboration and committed to pursue joint projects with the goal of ensuring a future in which patients have access to personalized care and support. The three cancer organizations and WBA agreed to collaborate on initiatives to develop and support innovative cancer research infrastructure and to share best practices to improve patient care.

  • The Zacks Analyst Blog Highlights: Walmart, Facebook, Walgreens, Target and Costco
    Zacks12 days ago

    The Zacks Analyst Blog Highlights: Walmart, Facebook, Walgreens, Target and Costco

    The Zacks Analyst Blog Highlights: Walmart, Facebook, Walgreens, Target and Costco

  • GuruFocus.com13 days ago

    Stocks That Fell to 3-Year Lows in the Week of May 10

    Newmont Goldcorp Corp. (NEM), Walgreens Boots Alliance Inc. (WBA), UBS Group AG (UBS), and Halliburton Co. (HAL) have declined to their respective three-year lows.

  • Buy Walmart (WMT) Stock Ahead of Q1 Fiscal 2020 Earnings Thursday?
    Zacks15 days ago

    Buy Walmart (WMT) Stock Ahead of Q1 Fiscal 2020 Earnings Thursday?

    Is it time to buy Walmart (WMT) stock heading into its first-quarter fiscal 2020 earnings release on Thursday, May 16?

  • Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
    Zacks16 days ago

    Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know

    Walgreens Boots Alliance (WBA) closed the most recent trading day at $53.56, moving +0.11% from the previous trading session.

  • InvestorPlace16 days ago

    6 Signs That Marijuana Legalization is Closer Than You Think

    It's become trendy for stock "gurus" to start pushing marijuana stocks. A few months ago, most of them were silent on the issue. Now they all seem to be pounding the table.I urged people to consider cannabis stocks back in 2014 - for one simple reason: Colorado had opened the door by being the first U.S. state to legalize recreational marijuana.Since then, Colorado has made over $6 billion in legal marijuana sales in just four years. This has produced more than $927 million in tax revenue. Some of the biggest names in U.S. legal cannabis operate there, like Charlotte's Web (OTCMKTS:CWBHF) and Elixinol Global (OTCMKTS:ELLXF), and they are flourishing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFrom the beginning, I knew that was just the first "domino" to fall… leading to full, federal legalization.Given that we've been under marijuana prohibition for generations, many folks are still skeptical. Well, based on the facts, news, and trends - not a gut feeling for or against marijuana - I do expect legalization, and soon. And I've got six reasons why. * 7 Dangerous Dividend Stocks to Stay Far Away From Catalyst 1: SAFE Banking Act & STATES ActThe first official step to full-blown legalization will likely be one of two specific bills that are working their way through Congress.In March, the Secure and Fair Enforcement (SAFE) Banking Act passed the U.S. House Committee on Financial Services with bipartisan support. If passed, the bill will allow banks to work with marijuana companies without fear of breaking any laws.Only a small number of regional banks and credit unions currently take the risk of offering services to the industry. Banking costs for marijuana companies are exceptionally high - try $5,000 a month maintenance fees! - due to the risk banks are taking by technically breaking federal laws. So, access to traditional banks/loans would be a game-changer.The other piece of legislation, the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, will allow individual states to make their own laws on cannabis, including banking. Any bank lawfully working with marijuana businesses will be protected under the STATES Act.At least one of these bills will likely be passed in the coming months, and possibly both. Either would be a major step toward legalizing marijuana in the United States. Catalyst 2: The 2020 ElectionNote: Please understand that my analysis on politics and the stock market is 100% from an investing point of view. I have no desire to push any type of politics on you in any manner. I hate it when other people do that to me, and I would never do it to you. My one and only goal is to make you money.The 2020 presidential election is already in the daily headlines. I've lost track of the number of Democrats that have thrown their hats into the ring. I know it's more than 20… and the election is still more than a year-and-a-half away!These candidates come from all types of backgrounds. Some are far left and others are more moderate. The candidates will undoubtedly take vicious shots at each other as they try to secure the Democratic nomination, but there is one topic that could create that kumbaya moment - marijuana.Nearly every Democratic candidate has called for legalization of even recreational marijuana as well expunging federal charges related to cannabis. Former Vice President Joe Biden is one major exception, but I don't think we've heard the last from him on this issue. Expect the topic to be at the forefront of town halls and debates over the next 18 months.In the meantime, several bills were introduced in the last year that would legalize marijuana nationwide. The one that has the best chance - and the backing of big-name Democrats - is the Marijuana Justice Act. It was originally introduced in 2017, but a vote never took place. New Jersey Senator Cory Booker reintroduced the bill in February. Its chances of getting through the Senate are very low, but the bill does put pressure on the Republicans up for re-election. That brings me to the next catalyst… Catalyst 3: President TrumpI have attended a few cannabis conferences recently, and I stay in touch with industry insiders. In just the last few months, I've noticed a significant increase in the number of insiders who expect President Trump to introduce a bill to legalize marijuana. Based on what I'm hearing from them and people who have connections in D.C., the odds of the president introducing such a bill are now well above 50%.We know President Trump wants another term, and according to a poll by Civilized, cannabis users plan to vote come November 3, 2020. Civilized is a pro legalization site, but about 90% of people surveyed said they intend to vote in the next presidential election. That's significant, and about 3% higher than non-cannabis consumers.Democrats will make sure marijuana is front and center in all debates. And it makes sense politically for Republicans, too. Backing marijuana's legalization will not hurt the party's voter base and could bring some moderates over to their side.That is where President Trump comes into play. If legalizing marijuana can swing some moderate Democrats to his side, he will not hesitate. I and others I talk with increasingly believe President Trump will strike preemptively and legalize marijuana before the election. Catalyst 4: The DEAMarijuana remains a Schedule 1 drug in the United States, which is one reason it is illegal. According to the Drug Enforcement Administration (DEA), Schedule 1 drugs are generally unsafe with a high potential for abuse and no accepted medical use.More and more studies refute all three of those criteria when it comes to marijuana. The last qualifier - no accepted medical use - is now known to be simply false.What will it take for the DEA to remove marijuana from Schedule 1? Well, the first thing is old-fashioned common sense. Heroin, LSD, and ecstasy are all Schedule 2 drugs, which in theory means they are less dangerous than marijuana. That's crazy. You don't need a medical or biology degree to see how out of touch and outdated that is.Beyond common sense, there are other things that will force the DEA to change marijuana's classification. The most likely are more studies demonstrating the positive medicinal effects of marijuana.This is yet another silly situation because government regulations make it extremely difficult to perform those studies. However, new Attorney General William Barr has said he supports more marijuana research, and the more individual states do, the higher the likelihood this will change.The bottom line is that the DEA's blessing is necessary for marijuana to be legalized. If all other parties, including Congress and President Trump, get behind legalization, the DEA will have no choice but to succumb to the pressure. Catalyst 5: The Farm BillSomething called the Farm Bill doesn't sound all that exciting, but believe me, it is. The bill legalized hemp in the United States for the first time in over 80 years.To be clear, the legalization of hemp did not have any direct effect on marijuana laws. But it did open up the conversation of doing the same thing with cannabis, which is important. If the Farm Bill was a test run of legalization, the government should be satisfied.We're already seeing demand for hemp-related goods. Products that include cannabidiol (CBD), the non-psychoactive part of the plant, are now found in food, drinks, skincare products, etc. What's more, they are available at places like CVS Health (NYSE:CVS), Walgreens (NASDAQ:WBA), and Bed, Bath & Beyond (NASDAQ:BBBY). The hemp-CBD market is expected to balloon 40X over the next few years. Catalyst 6: Money, Money, MoneyGood or bad, right or wrong, many decisions are made based on money. When it comes to marijuana, the dollar signs are too big to ignore.The amount of tax revenue that states could generate from legal marijuana is impressive. And when politicians of one state watch neighboring states bring in revenue, it puts pressure on them to get in on the action. Thus, the snowball effect of more states legalizing marijuana.Job creation is an often overlooked benefit of legalization. One study shows that marijuana could result in over 300,000 new jobs by 2020.California has already created 80,000 jobs in the marijuana industry, according to a study from ICF International. To put that into money terms - that is a $3.5 billion increase in labor income. And guess what? More income taxes as well.All states would love to have hundreds of millions in additional revenue. So would the federal government… which is a big reason for the bold prediction I'm making now.The United States is flying towards legalization, which means U.S. pot stocks have massive potential ahead. As an investor, you need to grab your slice of that pie. However you feel about marijuana, numbers don't lie, and getting in on the ground floor of a mega-trend like this is how you build explosive wealth.But it's critical to get in BEFORE America legalizes nationally.Marijuana stocks are about to deliver their next wave of wealth much quicker than you'd think. Click here for my presentation on the topic.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dangerous Dividend Stocks to Stay Far Away From * 7 Tips for New Investors Young and Old * 10 Great Stocks to Buy on Dips Compare Brokers The post 6 Signs That Marijuana Legalization is Closer Than You Think appeared first on InvestorPlace.

  • Why Walgreens Boots Alliance Stock Dropped 15.3% in April
    Motley Fool16 days ago

    Why Walgreens Boots Alliance Stock Dropped 15.3% in April

    The drugstore chain lamented its hardest-ever quarter last month. Here's what investors need to know.